Sphingosine-1-phosphate receptor 1 and Sphingosine-1-phosphate receptor 3 (S1PR1/S1PR3)

Sphingosine-1-phosphate receptor 1 (S1PR1) and sphingosine-1-phosphate receptor 3 (S1PR3) are class A G protein-coupled receptors that bind the bioactive lipid sphingosine-1-phosphate (S1P), a critical mediator of immune, vascular, and neural signaling. S1PR1 is essential for lymphocyte egress from lymphoid organs and regulation of vascular integrity, while S1PR3 facilitates cell proliferation, migration, and angiogenesis, and is implicated in tumor progression and aggressive cancer phenotypes. Both are validated therapeutic targets, with S1PR1 modulators approved for treating multiple sclerosis and others in development for inflammatory and oncological diseases. S1PR1 and S1PR3 are widely expressed and regulate a wide spectrum of physiological and pathological processes, often working in tandem, sometimes exhibiting nonredundant, subtype-specific biological effects.

Other names

S1P1EDG1endothelial differentiation gene 1S1P3EDG3endothelial differentiation gene 3

Agonists (e.g., fingolimod-phosphate): Functional antagonism by internalizing and degrading the receptor, sequestering lymphocytes in lymph nodes and reducing their migration to target tissues. Direct antagonism (e.g., specific S1PR3 antagonists): Blocks S1P-induced signal transduction pathways, inhibiting cell proliferation, migration, or immune cell trafficking. Immunomodulation: Downregulation of inflammatory cell migration, decreasing autoimmune activity, modulation of tumor microenvironment.